Click here to get full coverage on Is There Still Value In Biogen (BIIB) After The Recent Share Price Recovery - Yahoo Finance

Is There Still Value In Biogen (BIIB) After The Recent Share Price Recovery  Yahoo Finance

Is There Still Value In Biogen (BIIB) After The Recent Share Price Recovery - Yahoo Finance

Click here to get full coverage on Q4 and Full Year 2025 Earnings Call Webcast - Biogen

Q4 and Full Year 2025 Earnings Call Webcast  Biogen

Q4 and Full Year 2025 Earnings Call Webcast - Biogen

Click here to get full coverage on Biogen (BIIB) Valuation Check As High Dose Spinraza Wins Key European Approval - simplywall.st

Biogen (BIIB) Valuation Check As High Dose Spinraza Wins Key European Approval  simplywall.st

Biogen (BIIB) Valuation Check As High Dose Spinraza Wins Key European Approval - simplywall.st

Click here to get full coverage on Strong Cash Yield: Is Biogen Stock A Buy? - Trefis

Strong Cash Yield: Is Biogen Stock A Buy?  Trefis

Strong Cash Yield: Is Biogen Stock A Buy? - Trefis

Click here to get full coverage on Stocks making the biggest moves midday: Biogen, Rivian, Bank of America, Airbnb & more - CNBC

Stocks making the biggest moves midday: Biogen, Rivian, Bank of America, Airbnb & more  CNBC

Stocks making the biggest moves midday: Biogen, Rivian, Bank of America, Airbnb & more - CNBC

Click here to get full coverage on Bank of America Securities Keeps Their Hold Rating on Biogen (BIIB) - The Globe and Mail

Bank of America Securities Keeps Their Hold Rating on Biogen (BIIB)  The Globe and Mail

Bank of America Securities Keeps Their Hold Rating on Biogen (BIIB) - The Globe and Mail

Click here to get full coverage on Assessing Biogen (BIIB) Valuation After China Accepts Subcutaneous LEQEMBI Application - Sahm

Assessing Biogen (BIIB) Valuation After China Accepts Subcutaneous LEQEMBI Application  Sahm

Assessing Biogen (BIIB) Valuation After China Accepts Subcutaneous LEQEMBI Application - Sahm

Click here to get full coverage on June 2027 Options Now Available For Biogen (BIIB) - Nasdaq

June 2027 Options Now Available For Biogen (BIIB)  Nasdaq

June 2027 Options Now Available For Biogen (BIIB) - Nasdaq

Click here to get full coverage on Biogen: Why I Anticipate A Difficult 2026 For 'End Of An Era' Pharma (NASDAQ:BIIB) - Seeking Alpha

Biogen: Why I Anticipate A Difficult 2026 For 'End Of An Era' Pharma (NASDAQ:BIIB)  Seeking Alpha

Biogen: Why I Anticipate A Difficult 2026 For 'End Of An Era' Pharma (NASDAQ:BIIB) - Seeking Alpha

Click here to get full coverage on Here’s What Analysts Think About Biogen Inc. (BIIB) - Yahoo Finance

Here’s What Analysts Think About Biogen Inc. (BIIB)  Yahoo Finance

Here’s What Analysts Think About Biogen Inc. (BIIB) - Yahoo Finance

Click here to get full coverage on The Bull Case For Biogen (BIIB) Could Change Following EU Approval Of High‑Dose Spinraza Regimen - Sahm

The Bull Case For Biogen (BIIB) Could Change Following EU Approval Of High‑Dose Spinraza Regimen  Sahm

The Bull Case For Biogen (BIIB) Could Change Following EU Approval Of High‑Dose Spinraza Regimen - Sahm

Click here to get full coverage on The Bull Case For Biogen (BIIB) Could Change Following EU Approval Of High‑Dose Spinraza Regimen - simplywall.st

The Bull Case For Biogen (BIIB) Could Change Following EU Approval Of High‑Dose Spinraza Regimen  simplywall.st

The Bull Case For Biogen (BIIB) Could Change Following EU Approval Of High‑Dose Spinraza Regimen - simplywall.st

Click here to get full coverage on Biogen (BIIB) Stock Trades Up, Here Is Why - Yahoo Finance

Biogen (BIIB) Stock Trades Up, Here Is Why  Yahoo Finance

Biogen (BIIB) Stock Trades Up, Here Is Why - Yahoo Finance

Click here to get full coverage on HSBC Downgrades Biogen Inc. (BIIB) to Reduce Despite Pipeline Progress - Yahoo Finance

HSBC Downgrades Biogen Inc. (BIIB) to Reduce Despite Pipeline Progress  Yahoo Finance

HSBC Downgrades Biogen Inc. (BIIB) to Reduce Despite Pipeline Progress - Yahoo Finance

Click here to get full coverage on A Look at Biogen (BIIB) Valuation Following New Dravet Syndrome Study Results - Yahoo Finance

A Look at Biogen (BIIB) Valuation Following New Dravet Syndrome Study Results  Yahoo Finance

A Look at Biogen (BIIB) Valuation Following New Dravet Syndrome Study Results - Yahoo Finance

Click here to get full coverage on Biogen Inc. (BIIB): A Bull Case Theory - Yahoo Finance

Biogen Inc. (BIIB): A Bull Case Theory  Yahoo Finance

Biogen Inc. (BIIB): A Bull Case Theory - Yahoo Finance

Click here to get full coverage on What Biogen (BIIB)'s China Review for At‑Home LEQEMBI Injections Means For Shareholders - Yahoo Finance

What Biogen (BIIB)'s China Review for At‑Home LEQEMBI Injections Means For Shareholders  Yahoo Finance

What Biogen (BIIB)'s China Review for At‑Home LEQEMBI Injections Means For Shareholders - Yahoo Finance

Click here to get full coverage on Assessing Biogen (BIIB) Valuation After China Accepts LEQEMBI Subcutaneous License Application - Yahoo Finance

Assessing Biogen (BIIB) Valuation After China Accepts LEQEMBI Subcutaneous License Application  Yahoo Finance

Assessing Biogen (BIIB) Valuation After China Accepts LEQEMBI Subcutaneous License Application - Yahoo Finance

Click here to get full coverage on Biogen (BIIB): Assessing Valuation After Recent Share Price Gains - Yahoo Finance

Biogen (BIIB): Assessing Valuation After Recent Share Price Gains  Yahoo Finance

Biogen (BIIB): Assessing Valuation After Recent Share Price Gains - Yahoo Finance

Click here to get full coverage on Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance

Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?  Yahoo Finance

Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance

Click here to get full coverage on Biogen (BIIB) Anticipates Q4 Earnings Impact Due to R&D Costs - GuruFocus

Biogen (BIIB) Anticipates Q4 Earnings Impact Due to R&D Costs  GuruFocus

Biogen (BIIB) Anticipates Q4 Earnings Impact Due to R&D Costs - GuruFocus

Click here to get full coverage on Biogen: Competing With Eli Lilly's Kisunla, Safety Gives Market Edge (NASDAQ:BIIB) - Seeking Alpha

Biogen: Competing With Eli Lilly's Kisunla, Safety Gives Market Edge (NASDAQ:BIIB)  Seeking Alpha

Biogen: Competing With Eli Lilly's Kisunla, Safety Gives Market Edge (NASDAQ:BIIB) - Seeking Alpha

Click here to get full coverage on BIIB: Cost discipline, new therapies, and a strong pipeline set the stage for major growth from 2026 - TradingView — Track All Markets

BIIB: Cost discipline, new therapies, and a strong pipeline set the stage for major growth from 2026  TradingView — Track All Markets

BIIB: Cost discipline, new therapies, and a strong pipeline set the stage for major growth from 2026 - TradingView — Track All Markets

Click here to get full coverage on Biogen (BIIB) Anticipates Significant Q4 2025 Financial Impact f - GuruFocus

Biogen (BIIB) Anticipates Significant Q4 2025 Financial Impact f  GuruFocus

Biogen (BIIB) Anticipates Significant Q4 2025 Financial Impact f - GuruFocus

Click here to get full coverage on Jefferies Initiates Coverage on Biogen Inc. (BIIB) with Buy Rating and $190 PT - Yahoo Finance

Jefferies Initiates Coverage on Biogen Inc. (BIIB) with Buy Rating and $190 PT  Yahoo Finance

Jefferies Initiates Coverage on Biogen Inc. (BIIB) with Buy Rating and $190 PT - Yahoo Finance

Click here to get full coverage on Biogen (BIIB) Stock Is Up, What You Need To Know - Yahoo Finance

Biogen (BIIB) Stock Is Up, What You Need To Know  Yahoo Finance

Biogen (BIIB) Stock Is Up, What You Need To Know - Yahoo Finance

Click here to get full coverage on BIIB Stock: Is Biogen Still A Buy After The 14% Spike? - Forbes

BIIB Stock: Is Biogen Still A Buy After The 14% Spike?  Forbes

BIIB Stock: Is Biogen Still A Buy After The 14% Spike? - Forbes

Click here to get full coverage on Biogen Inc (BIIB) Q3 2025 Earnings Call Highlights: Strong Product Launch Growth and Strategic ... - Yahoo Finance

Biogen Inc (BIIB) Q3 2025 Earnings Call Highlights: Strong Product Launch Growth and Strategic ...  Yahoo Finance

Biogen Inc (BIIB) Q3 2025 Earnings Call Highlights: Strong Product Launch Growth and Strategic ... - Yahoo Finance

Click here to get full coverage on Biogen Inc. (BIIB) Q3 Earnings and Revenues Top Estimates - Nasdaq

Biogen Inc. (BIIB) Q3 Earnings and Revenues Top Estimates  Nasdaq

Biogen Inc. (BIIB) Q3 Earnings and Revenues Top Estimates - Nasdaq

Click here to get full coverage on Assessing Biogen (BIIB) Valuation After China Accepts Subcutaneous LEQEMBI Application - simplywall.st

Assessing Biogen (BIIB) Valuation After China Accepts Subcutaneous LEQEMBI Application  simplywall.st

Assessing Biogen (BIIB) Valuation After China Accepts Subcutaneous LEQEMBI Application - simplywall.st

Click here to get full coverage on Higher-dose spinal muscular atrophy treatment approved for patients in EU - Stock Titan

Higher-dose spinal muscular atrophy treatment approved for patients in EU  Stock Titan

Higher-dose spinal muscular atrophy treatment approved for patients in EU - Stock Titan

Click here to get full coverage on Therapeutics Stocks Q3 In Review: Biogen (NASDAQ:BIIB) Vs Peers - Yahoo Finance

Therapeutics Stocks Q3 In Review: Biogen (NASDAQ:BIIB) Vs Peers  Yahoo Finance

Therapeutics Stocks Q3 In Review: Biogen (NASDAQ:BIIB) Vs Peers - Yahoo Finance

Click here to get full coverage on H.C. Wainwright Affirms Biogen Inc. (BIIB) Buy Rating on Lupus Franchise Prospects - Yahoo Finance

H.C. Wainwright Affirms Biogen Inc. (BIIB) Buy Rating on Lupus Franchise Prospects  Yahoo Finance

H.C. Wainwright Affirms Biogen Inc. (BIIB) Buy Rating on Lupus Franchise Prospects - Yahoo Finance

Click here to get full coverage on GRIMES & Co WEALTH MANAGEMENT LLC Sells 5,727 Shares of Biogen Inc. $BIIB - MarketBeat

GRIMES & Co WEALTH MANAGEMENT LLC Sells 5,727 Shares of Biogen Inc. $BIIB  MarketBeat

GRIMES & Co WEALTH MANAGEMENT LLC Sells 5,727 Shares of Biogen Inc. $BIIB - MarketBeat

Click here to get full coverage on Biogen (BIIB) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance

Biogen (BIIB) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates  Yahoo Finance

Biogen (BIIB) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance

Click here to get full coverage on Biogen Inc. (BIIB)’s Alzheimer’s Drug Leqembi Wins EU Nod, Now Approved in 48 Countries - Yahoo Finance

Biogen Inc. (BIIB)’s Alzheimer’s Drug Leqembi Wins EU Nod, Now Approved in 48 Countries  Yahoo Finance

Biogen Inc. (BIIB)’s Alzheimer’s Drug Leqembi Wins EU Nod, Now Approved in 48 Countries - Yahoo Finance

Click here to get full coverage on Canaccord Genuity Reiterates a Buy on Biogen (BIIB) - Yahoo Finance

Canaccord Genuity Reiterates a Buy on Biogen (BIIB)  Yahoo Finance

Canaccord Genuity Reiterates a Buy on Biogen (BIIB) - Yahoo Finance

Click here to get full coverage on Biogen (BIIB) Stock Trades Down, Here Is Why - Yahoo Finance

Biogen (BIIB) Stock Trades Down, Here Is Why  Yahoo Finance

Biogen (BIIB) Stock Trades Down, Here Is Why - Yahoo Finance

Click here to get full coverage on Biogen Inc. (BIIB) Stock Analysis: Navigating a 1.82% Potential Upside Amid Strategic Developments - DirectorsTalk Interviews

Biogen Inc. (BIIB) Stock Analysis: Navigating a 1.82% Potential Upside Amid Strategic Developments  DirectorsTalk Interviews

Biogen Inc. (BIIB) Stock Analysis: Navigating a 1.82% Potential Upside Amid Strategic Developments - DirectorsTalk Interviews

Click here to get full coverage on BIIB Q2 Deep Dive: New Launches Offset Legacy Pressure, Pipeline Advancements Drive Guidance - Yahoo Finance

BIIB Q2 Deep Dive: New Launches Offset Legacy Pressure, Pipeline Advancements Drive Guidance  Yahoo Finance

BIIB Q2 Deep Dive: New Launches Offset Legacy Pressure, Pipeline Advancements Drive Guidance - Yahoo Finance

Click here to get full coverage on 3 Reasons to Sell BIIB and 1 Stock to Buy Instead - Barchart.com

3 Reasons to Sell BIIB and 1 Stock to Buy Instead  Barchart.com

3 Reasons to Sell BIIB and 1 Stock to Buy Instead - Barchart.com

Click here to get full coverage on 3 Reasons BIIB is Risky and 1 Stock to Buy Instead - Yahoo Finance

3 Reasons BIIB is Risky and 1 Stock to Buy Instead  Yahoo Finance

3 Reasons BIIB is Risky and 1 Stock to Buy Instead - Yahoo Finance

Click here to get full coverage on BIIB Q3 Deep Dive: New Product Launches Offset Guidance Cut, R&D Pipeline Expands - Yahoo Finance

BIIB Q3 Deep Dive: New Product Launches Offset Guidance Cut, R&D Pipeline Expands  Yahoo Finance

BIIB Q3 Deep Dive: New Product Launches Offset Guidance Cut, R&D Pipeline Expands - Yahoo Finance

Click here to get full coverage on Biogen (BIIB) Expands Neurology Pipeline With Alcyone Buyout, Stock Seen Undervalued - Yahoo Finance

Biogen (BIIB) Expands Neurology Pipeline With Alcyone Buyout, Stock Seen Undervalued  Yahoo Finance

Biogen (BIIB) Expands Neurology Pipeline With Alcyone Buyout, Stock Seen Undervalued - Yahoo Finance

Click here to get full coverage on Biogen (BIIB): One-Time $471M Loss Raises Fresh Doubts Over Rebounding Profit Narrative - Yahoo Finance

Biogen (BIIB): One-Time $471M Loss Raises Fresh Doubts Over Rebounding Profit Narrative  Yahoo Finance

Biogen (BIIB): One-Time $471M Loss Raises Fresh Doubts Over Rebounding Profit Narrative - Yahoo Finance

Click here to get full coverage on Fund Update: 282,084 BIOGEN (BIIB) shares added to Zurcher Kantonalbank (Zurich Cantonalbank) portfolio - Quiver Quantitative

Fund Update: 282,084 BIOGEN (BIIB) shares added to Zurcher Kantonalbank (Zurich Cantonalbank) portfolio  Quiver Quantitative

Fund Update: 282,084 BIOGEN (BIIB) shares added to Zurcher Kantonalbank (Zurich Cantonalbank) portfolio - Quiver Quantitative

Click here to get full coverage on Is New Neurology Data And Partnerships Altering The Investment Case For Biogen (BIIB)? - Yahoo Finance

Is New Neurology Data And Partnerships Altering The Investment Case For Biogen (BIIB)?  Yahoo Finance

Is New Neurology Data And Partnerships Altering The Investment Case For Biogen (BIIB)? - Yahoo Finance

Click here to get full coverage on Should Biogen’s (BIIB) Surging New Drug Sales Reshape Investors’ Expectations for Future Growth? - Yahoo Finance

Should Biogen’s (BIIB) Surging New Drug Sales Reshape Investors’ Expectations for Future Growth?  Yahoo Finance

Should Biogen’s (BIIB) Surging New Drug Sales Reshape Investors’ Expectations for Future Growth? - Yahoo Finance

Click here to get full coverage on RBC Capital Maintains a Buy on Biogen (BIIB) With a $208 PT - Yahoo Finance

RBC Capital Maintains a Buy on Biogen (BIIB) With a $208 PT  Yahoo Finance

RBC Capital Maintains a Buy on Biogen (BIIB) With a $208 PT - Yahoo Finance

Click here to get full coverage on Jefferies Maintains Biogen(BIIB.US) With Buy Rating, Raises Target Price to $210 - 富途牛牛

Jefferies Maintains Biogen(BIIB.US) With Buy Rating, Raises Target Price to $210  富途牛牛

Jefferies Maintains Biogen(BIIB.US) With Buy Rating, Raises Target Price to $210 - 富途牛牛

Click here to get full coverage on Amazon’s ‘Handy’ Multitool Pen Is Now Only $8 — And It Makes a Great Stocking Stuffer - Autoblog

Amazon’s ‘Handy’ Multitool Pen Is Now Only $8 — And It Makes a Great Stocking Stuffer  Autoblog

Amazon’s ‘Handy’ Multitool Pen Is Now Only $8 — And It Makes a Great Stocking Stuffer - Autoblog

Click here to get full coverage on Biogen to Report Third Quarter 2025 Financial Results October 30, 2025 - Biogen

Biogen to Report Third Quarter 2025 Financial Results October 30, 2025  Biogen

Biogen to Report Third Quarter 2025 Financial Results October 30, 2025 - Biogen

Click here to get full coverage on Biogen (NASDAQ:BIIB) Reports Bullish Q2 - Yahoo Finance

Biogen (NASDAQ:BIIB) Reports Bullish Q2  Yahoo Finance

Biogen (NASDAQ:BIIB) Reports Bullish Q2 - Yahoo Finance

Click here to get full coverage on LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025" - PR Newswire

LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"  PR Newswire

LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025" - PR Newswire

Click here to get full coverage on Biogen (BIIB): Reassessing Valuation After a Recent 3-Month Share Price Rebound - Yahoo Finance

Biogen (BIIB): Reassessing Valuation After a Recent 3-Month Share Price Rebound  Yahoo Finance

Biogen (BIIB): Reassessing Valuation After a Recent 3-Month Share Price Rebound - Yahoo Finance

Click here to get full coverage on Why Biogen (BIIB) Is Up 6.4% After At-Home Alzheimer’s Therapy and Dravet Data Updates - Yahoo Finance

Why Biogen (BIIB) Is Up 6.4% After At-Home Alzheimer’s Therapy and Dravet Data Updates  Yahoo Finance

Why Biogen (BIIB) Is Up 6.4% After At-Home Alzheimer’s Therapy and Dravet Data Updates - Yahoo Finance

Click here to get full coverage on BIIB Beats on Q3 Earnings & Sales, Stock Down on Lowered '25 EPS View - October 30, 2025 - Zacks Investment Research

BIIB Beats on Q3 Earnings & Sales, Stock Down on Lowered '25 EPS View - October 30, 2025  Zacks Investment Research

BIIB Beats on Q3 Earnings & Sales, Stock Down on Lowered '25 EPS View - October 30, 2025 - Zacks Investment Research

Click here to get full coverage on Did China’s At‑Home LEQEMBI Review Just Shift Biogen's (BIIB) Alzheimer’s Care Investment Narrative? - Sahm

Did China’s At‑Home LEQEMBI Review Just Shift Biogen's (BIIB) Alzheimer’s Care Investment Narrative?  Sahm

Did China’s At‑Home LEQEMBI Review Just Shift Biogen's (BIIB) Alzheimer’s Care Investment Narrative? - Sahm

Click here to get full coverage on Biogen’s IND for BIIB-142 accepted by FDA - BioWorld MedTech

Biogen’s IND for BIIB-142 accepted by FDA  BioWorld MedTech

Biogen’s IND for BIIB-142 accepted by FDA - BioWorld MedTech

Click here to get full coverage on Biogen (BIIB) Receives a Hold from Bank of America Securities - The Globe and Mail

Biogen (BIIB) Receives a Hold from Bank of America Securities  The Globe and Mail

Biogen (BIIB) Receives a Hold from Bank of America Securities - The Globe and Mail

Click here to get full coverage on HSBC Downgrades Biogen (BIIB) with New Target Price | BIIB Stock News - GuruFocus

HSBC Downgrades Biogen (BIIB) with New Target Price | BIIB Stock News  GuruFocus

HSBC Downgrades Biogen (BIIB) with New Target Price | BIIB Stock News - GuruFocus

Click here to get full coverage on BIIB's sNDA for Higher Dose of SMA Drug Spinraza Gets FDA's CRL - Yahoo Finance

BIIB's sNDA for Higher Dose of SMA Drug Spinraza Gets FDA's CRL  Yahoo Finance

BIIB's sNDA for Higher Dose of SMA Drug Spinraza Gets FDA's CRL - Yahoo Finance

Click here to get full coverage on 3 Reasons to Sell BIIB and 1 Stock to Buy Instead - FinancialContent

3 Reasons to Sell BIIB and 1 Stock to Buy Instead  FinancialContent

3 Reasons to Sell BIIB and 1 Stock to Buy Instead - FinancialContent

Click here to get full coverage on Biogen (BIIB) Valuation in Focus After FDA Nod for At-Home Leqembi, Dravet Therapy Progress - simplywall.st

Biogen (BIIB) Valuation in Focus After FDA Nod for At-Home Leqembi, Dravet Therapy Progress  simplywall.st

Biogen (BIIB) Valuation in Focus After FDA Nod for At-Home Leqembi, Dravet Therapy Progress - simplywall.st

Click here to get full coverage on Trial of new Dravet syndrome drug moves faster, with key results in 2027 - Stock Titan

Trial of new Dravet syndrome drug moves faster, with key results in 2027  Stock Titan

Trial of new Dravet syndrome drug moves faster, with key results in 2027 - Stock Titan

Click here to get full coverage on Biogen Inc. (BIIB) Q3 Earnings and Revenues Top Estimates - Yahoo Finance

Biogen Inc. (BIIB) Q3 Earnings and Revenues Top Estimates  Yahoo Finance

Biogen Inc. (BIIB) Q3 Earnings and Revenues Top Estimates - Yahoo Finance

Click here to get full coverage on We Think Biogen's (NASDAQ:BIIB) Profit Is Only A Baseline For What They Can Achieve - Yahoo Finance

We Think Biogen's (NASDAQ:BIIB) Profit Is Only A Baseline For What They Can Achieve  Yahoo Finance

BIIB

Price Chart

Key Statistics

Technicals

About BIIB

Latest News

Is There Still Value In Biogen (BIIB) After The Recent Share Price Recovery - Yahoo Finance

Q4 and Full Year 2025 Earnings Call Webcast - Biogen

Biogen (BIIB) Valuation Check As High Dose Spinraza Wins Key European Approval - simplywall.st

Advanced Charts

Top Gainers

Top Losers